On January 18, 2024 BostonGene, a leading provider of AI-based molecular and immune profiling solutions provider, reported a collaboration with Prisma Health aimed at advancing the understanding of rare tumors by characterizing the tumor microenvironment (TME), mutational landscape and host immune profiles of patients treated with immune checkpoint inhibitors (Press release, BostonGene, JAN 18, 2024, View Source [SID1234639343]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In collaboration with Prisma Health’s Rare Tumor Center, BostonGene will analyze tissue and peripheral blood from rare cancer solid-tumor patients to understand the molecular underpinnings of immune-activating drugs commonly used to enhance a person’s innate mechanisms to fight cancer. BostonGene will perform detailed analyses of primary tumors and immunoprofiling of matched peripheral blood collected during this cohort of the trial, which is currently enrolling patients.
Prisma Health, the largest healthcare system in South Carolina, established its Rare Tumor Center in 2014 with a focus on improved outcomes for patients with rare cancers. By adding AI-powered molecular profiling to its long-running prospective clinical trial on checkpoint inhibitors, Prisma Health’s physician researchers hope to gain a substantially deeper understanding, not just of cancer, but of cancer’s interaction with the surrounding tissue and normal supportive cells. The center is part of the Prisma Health Cancer Institute, which actively participates in more than 300 clinical trials annually.
"BostonGene’s innovative solutions will provide a substantially deeper understanding of the molecular profiles of rare tumor patients, which could help us better determine what therapies work for which patients," said Jeffrey Edenfield, MD, medical director for Prisma Health’s Institute for Translational Oncology Research and founder of its Rare Tumor Center. "We are excited about the opportunity to identify potential molecular markers of treatment response and, in turn, improve patient outcomes."
"We’re honored to collaborate with Prisma Health for this prospective clinical trial," said Nathan Fowler, MD, chief medical officer at BostonGene. "We are confident that our next-generation multi-omics analytics will uncover unique molecular characteristics that can be utilized to personalize treatment plans for patients with rare tumors."
BostonGene’s computational platform integrates genomic, transcriptomic and immunoprofiling data to assess the TME and corresponding host immune status to characterize somatic alterations, gene expression, fusions, tumor heterogeneity, the TME and immunoprofiles.
Visit ClinicalTrials.gov for more information on the protocol, A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Rare Solid Tumors.